US FTC suspends challenge to block Amgen’s $27.8 billion deal…
(Reuters) -The U.S. Federal Trade Commission (FTC) has suspended its challenge of…
N2:HEA
US govt awards $1.4 billion for development of new COVID therapies,…
(Reuters) - The U.S. government said on Tuesday it had awarded $1.4 billion for the…
US FDA puts Gilead Sciences blood cancer drug studies on hold
(Reuters) -Gilead Sciences said on Monday the U.S. health regulator placed a clinical…
Moderna’s updated COVID vaccine effective against…
(Reuters) - Moderna said on Thursday an initial study data showed its updated COVID-19…
Norfolk Southern agrees to boost safety at Ohio derailment site, US…
By David Shepardson WASHINGTON (Reuters) - Norfolk Southern Corp has agreed to improve…
AbbVie trims forecast for Humira sales drop on favorable coverage
By Leroy Leo and Patrick Wingrove (Reuters) -AbbVie on Thursday trimmed its 2023 view for…
California, other states move to block 3M’s $10.3 billion PFAS…
By Clark Mindock (Reuters) -A group of 22 states and U.S. territories on Wednesday moved…
J&J upbeat on 2023 as devices rebound post-COVID, shares jump
By Bhanvi Satija and Patrick Wingrove (Reuters) -Johnson & Johnson on Thursday…
AT&T shares hit three-decade low as lead cables risk weighs
By Chibuike Oguh NEW YORK (Reuters) -Shares of AT&T Inc fell nearly 7% to hit their…
Acumen’s Alzheimer’s drug passes initial safety test
By Julie Steenhuysen CHICAGO (Reuters) - An experimental Alzheimer's disease drug…